Targeted drug delivery
Cancer pain
Patient selection and clinical evidence
Helping patients manage cancer pain with targeted drug delivery
Targeted drug delivery is effective in reducing or eliminating the need for systemic opioids when used to treat cancer-related pain.1
SynchroMed™ implantable infusion system
The SynchroMed™ III implantable infusion system delivers prescribed medication directly into the intrathecal space, thereby bypassing the blood-brain barrier. As result, only a fraction of the oral dose is needed to sustain pain relief.2
Patient selection and referral guidelines: targeted drug delivery for cancer-related pain
For many cancer patients, oral analgesics may be adequate; however, those cancer patients with intractable pain who meet any of the criteria listed below may be appropriate for more advanced pain management techniques including targeted drug delivery (TDD) using intrathecal opioids. These patients may be candidates for targeted drug delivery (TDD) using intrathecal opioids to control pain.
Pending a successful intrathecal morphine trial, a permanent intrathecal catheter and Medtronic SynchroMed™ III programmable pump may help control your patients’ pain.
Selection guidelines: targeted drug delivery for cancer patients
Cancer patients with intractable pain who meet any of the criteria below may be candidates targeted drug delivery with SynchroMed™ III
- Symptoms of pain due to advanced stage cancer at presentation, with a minimum life expectancy of >3 months.3,4,8,9
- Refractory to conventional pain management because of intractable drug adverse effects or unsatisfactory analgesia.3,4,8,9
- Visual analog scale (VAS) of ≥ 5, despite 200 mg/day of oral morphine or the analgesic equivalent.†,3,8,9
Consider patients on lower doses if opioid side effects are refractory to conservative treatment and severe enough to prevent upward titration3,8,9
Note: It is important to consider increased assessment and referral vigilance for women,5–7,10 minorities,5–7,11 and the elderly,5,6,11 who have been shown to be at increased risk for inadequate analgesia.
Clinical outcomes
Refractory cancer pain
Study highlights
Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain:3
- Prospective, multicenter, randomized
- 200 patients with advanced cancer and refractory pain
- Patients randomly assigned to receive comprehensive medical management (CMM) or intrathecal drug delivery (IDDS) plus CMM, 100 per arm
- Intrathecal drug delivery was delivered by the SynchroMed™ programmable infusion system
- Entry criteria included visual analog scale (VAS) pain score of ≥5 on a 0–10 scale despite 200 mg/day of oral morphine or its equivalent, or lower doses with intolerable side effects
- Demographic and clinical characteristics were well balanced.
Medtronic provides results based on proximity to the search criteria. The results shown here are populated by your selections and may not include the full list of available providers.
Medtronic provides this listing to assist indicated patients’ access to care. Medtronic has no vested interest in any specific provider, nor do we provide any recommendation, assurance, or guarantee with respect to their service. Medtronic does not verify or monitor the license, credentials, accreditations or qualifications of any provider listed in the Physician Finder. Information on this site should not be used as a substitute for physician consultation. Patients should always talk with their provider about diagnosis and treatment information. The list of providers may not include all of those in your area who are qualified to deliver care. There is no cost associated for providers to be included on this list. Some providers on this list may purchase products from Medtronic or may act as paid consultants to Medtronic.